Our systematic review synthesizing data from eight high-quality RCTs and pooled analyses demonstrates that GLP-1 RAs, particularly semaglutide, offer meaningful CV benefits in patients with T2DM, especially those with coexisting ASCVD, CKD, or HFpEF. This evidence concerns the gene GLP1R and chronic kidney disease.